Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
1. A pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) benzoate and one or more pharmaceutically acceptable carriers or excipients.
2. The pharmaceutical composition of claim 1 , wherein the composition comprises one or more of a mucoadhesive enhancer, a penetrating enhancer, a cationic polymer, a cyclodextrin, a Tight Junction Modulator, an enzyme inhibitor, a surfactant, a chelator, or a polysaccharide.
3. The pharmaceutical composition of claim 1 , wherein the composition comprises one or more of chitosan, a chitosan derivative, β-cyclodextrin, Clostridium perfringens enterotoxin, zonula occludens toxin (ZOT), human neutrophil elastase inhibitor (ER143), sodium taurocholate, sodium deoxycholate sodium, sodium lauryl sulphate, glycodeoxycholat, palmitic acid, palmitoleic acid, stearic acid, oleyl acid, oleyl alchohol, capric acid sodium salt, DHA, EPA, dipalmitoyl phophatidyl choline, soybean lecithin, lysophosphatidylcholine, dodecyl maltoside, tetradecyl maltoside, EDTA, lactose, cellulose, or citric acid.
4. The pharmaceutical composition of claim 1 , wherein the composition is formulated for intranasal administration.
5. The pharmaceutical composition of claim 4 , wherein the composition is formulated as a powder.
6. The pharmaceutical composition of claim 5 , wherein the powder is a free-flowing powder.
7. The pharmaceutical composition of claim 6 , wherein the powder comprises particles having a median diameter less than 2000 μm and/or greater than 0.5 μm.
8. The pharmaceutical composition of claim 6 , wherein the powder has a particle size distribution including a d10 of 20-60 μm, a d50 of 80-120 μm, and/or a d90 of 130-300 μm.
9. The pharmaceutical composition of claim 1 , wherein the 5-MeO-DMT benzoate is crystalline and is characterised by peaks in an XRPD diffractogram at 17.5, 17.7 and 21.0° 2θ±0.1° 2θ as measured by x-ray powder diffraction using an x-ray wavelength of 1.5406 Å.
10. A nasal delivery device comprising a powder comprising a pharmaceutically effective amount of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) benzoate and one or more pharmaceutically acceptable carriers or excipients.
11. The nasal delivery device of claim 10 , wherein the nasal delivery device is a unit-dose dry powder inhaler.
12. The nasal delivery device of claim 10 , wherein the nasal delivery device comprises crystalline 5-MeO-DMT benzoate as characterised by peaks in an XRPD diffractogram at 17.5, 17.7 and 21.0° 2θ±0.1° 2θ as measured by x-ray powder diffraction using an x-ray wavelength of 1.5406 Å.
13. A method of treating depression in a subject, the method comprising intranasally administering a pharmaceutically effective amount of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) benzoate to the subject to treat depression.
14. The method of claim 13 , wherein the method comprises intranasally administering 1 mg to 10 mg of 5-MeO-DMT benzoate.
15. The method of claim 13 , wherein the 5-MeO-DMT benzoate is crystalline and is characterised by peaks in an XRPD diffractogram at 17.5, 17.7 and 21.0° 2θ±0.1° 2θ as measured by x-ray powder diffraction using an x-ray wavelength of 1.5406 Å.